Acorda Therapeutics (FRA:CDG) Accounts Payable & Accrued Expense : €25.4 Mil (As of Mar. 2024)

View and export this data going back to 2006. Start your Free Trial

What is Acorda Therapeutics Accounts Payable & Accrued Expense?

Acorda Therapeutics's quarterly accounts payable & accrued expense declined from Sep. 2023 (€39.0 Mil) to Dec. 2023 (€33.2 Mil) and declined from Dec. 2023 (€33.2 Mil) to Mar. 2024 (€25.4 Mil).

Acorda Therapeutics's annual accounts payable & accrued expense declined from Dec. 2021 (€31.9 Mil) to Dec. 2022 (€30.2 Mil) but then increased from Dec. 2022 (€30.2 Mil) to Dec. 2023 (€33.2 Mil).

Acorda Therapeutics Accounts Payable & Accrued Expense Historical Data

The historical data trend for Acorda Therapeutics's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acorda Therapeutics Accounts Payable & Accrued Expense Chart

Acorda Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

58.80

41.37

31.94

30.22

33.19

Acorda Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															27.90	23.07	39.05	33.19	25.39

Acorda Therapeutics Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Acorda Therapeutics (FRA:CDG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Acorda Therapeutics Inc (FRA:CDG) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

ACOR:USA

Address

2 Blue Hill Plaza, 3rd Floor, Pearl River, New York, NY, USA, 10965

Website

https://www.acorda.com

Acorda Therapeutics Inc is a biopharmaceutical company engaged in developing therapies that restore function and improve the lives of people with neurological disorders. The company market Inbrija (levodopa inhalation powder), which is approved in the U.S. for intermittent treatment of OFF episodes, also known as OFF periods, in people with Parkinson's disease treated with carbidopa/levodopa. Inbrija is for as-needed use and utilizes the ARCUS pulmonary delivery system, a technology platform designed to deliver medication through inhalation. The company also markets branded Ampyra (dalfampridine) Extended-Release Tablets, 10 mg to improve walking in adults with multiple sclerosis.

Acorda Therapeutics (FRA:CDG) Headlines

No Headlines